Clinical trial
A Phase 1b/2a Randomized, Double-Blind, Placebo-controlled Study of the Safety and Efficacy of MAR001 in Patients With Metabolic Dysfunction
NCT05896254 is registered in ClinicalTrials.gov with Marea Therapeutics as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase 1b/2a Randomized, Double-Blind, Placebo-controlled Study of the Safety and Efficacy of MAR001 in Patients With Metabolic Dysfunction
- Lead sponsor
- Marea Therapeutics
- Phase
- Phase 1/2
- Overall status
- Completed
- Start date
- July 22, 2023
- Completion date
- December 13, 2024
- Enrollment
- 55 (actual)
- Sites
- 2
Conditions
As the registry lists them; a condition with its own page is linked.